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Abstract
HIV-1 Gag drives a number of events during the genesis of virions and is the only viral protein required for the assembly of
virus-like particles in vitro and in cells. Although a reasonable understanding of the processes that accompany the later
stages of HIV-1 assembly has accrued, events that occur at the initiation of assembly are less well defined. In this regard,
important uncertainties include where in the cell Gag first multimerizes and interacts with the viral RNA, and whether Gag-
RNA interaction requires or induces Gag multimerization in a living cell. To address these questions, we developed assays in
which protein crosslinking and RNA/protein co-immunoprecipitation were coupled with membrane flotation analyses in
transfected or infected cells. We found that interaction between Gag and viral RNA occurred in the cytoplasm and was
independent of the ability of Gag to localize to the plasma membrane. However, Gag:RNA binding was stabilized by the C-
terminal domain (CTD) of capsid (CA), which participates in Gag-Gag interactions. We also found that Gag was present as
monomers and low-order multimers (e.g. dimers) but did not form higher-order multimers in the cytoplasm. Rather, high-
order multimers formed only at the plasma membrane and required the presence of a membrane-binding signal, but not a
Gag domain (the CA-CTD) that is essential for complete particle assembly. Finally, sequential RNA-immunoprecipitation
assays indicated that at least a fraction of Gag molecules can form multimers on viral genomes in the cytoplasm. Taken
together, our results suggest that HIV-1 particle assembly is initiated by the interaction between Gag and viral RNA in the
cytoplasm and that this initial Gag-RNA encounter involves Gag monomers or low order multimers. These interactions per se
do not induce or require high-order Gag multimerization in the cytoplasm. Instead, membrane interactions are necessary for
higher order Gag multimerization and subsequent particle assembly in cells.
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Introduction
Assembly of human immunodeficiency virus type 1 (HIV-1) is a
multi-step process that is driven and coordinated by the viral Gag
protein. During assembly, Gag molecules selectively recruit
unspliced viral genomic RNA for packaging into virions from a
large pool of cellular RNA molecules. The Gag:RNA interaction is
mediated by the nucleocapsid (NC) domain of Gag that binds
directly to the packaging sequence (psi), which is composed of four
stem loops located within the 59 UTR and the 59 end of the gag
gene [1,2,3,4]. Another key event is the recruitment of Gag
molecules to the plasma membrane, the major site for productive
HIV-1 assembly [5,6,7]. Plasma membrane targeting is directed
by functions in the matrix (MA) domain, consisting of the N-
terminal myristoyl group [8,9] as well as a cluster of basic amino
acids [10] and other residues that confer specific recognition of
PI(3,4)P2 [11,12,13]. Subsequent steps in HIV-1 assembly include
the oligomerization of a few thousand Gag molecules around a
nucleating core Gag:RNA complex at the plasma membrane, a
process driven by the capsid (CA) and NC domains of Gag
[14,15,16,17]. The final step is the recruitment of cellular factors
that enable virion budding by the C-terminal p6 domain
[18,19,20]. After the release of particles from the cell surface, a
number of proteolytic cleavage events in Gag lead to major
structural changes, yielding infectious virions.
Gag multimerization is obviously a key event in HIV-1 assembly
and multiple domains of Gag, including MA, CA and NC, have
been proposed to play a role in this process. Although biochemical
and structural studies [21] indicate that recombinant MA can
form trimers, MA is not likely to be the driving force for Gag
multimerization, as Gag proteins lacking most or all of MA can
assemble into virus particles [22,23,24,25]. Conversely, the role of
CA and NC in Gag multimerization and accurate particle
assembly has been substantiated in a variety of experimental
settings. In particular, mutations affecting the C-terminal domain
(CTD) of CA disrupt assembly [26,27,28,29], a finding supported
by structural data [30]. Additionally, although it is not required for
the early stages of virion assembly [31], the N-terminal domain
(NTD) of CA mediates CA multimerization in mature virions
through the formation of CA hexamers [26,28,29,32,33]. A
number of studies have indicated that NC contributes to Gag
multimerization, mainly by virtue of its basic residues that are
important for RNA binding [34,35,36,37]. It is likely that NC
mediates Gag-Gag interactions indirectly, through recruitment of
viral RNA that plays a structural role in virions [38] by serving as a
scaffold for Gag multimerization. This view is supported by the
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[39,40,41], whereas removal of RNA results in disruption of
particles [38,39]. Likewise, RNase treatment of recombinant
Gag [35] or Gag/Gag-Pol complexes [42] inhibits Gag-Gag
interaction.
The notion that viral RNA plays an important role in HIV-1
assembly raises two important and related questions about early
events in the process. The first is where in the cell Gag initially
interacts with viral RNA. Two potential sites are the cytoplasm
and plasma membrane. Initiation of RNA packaging at the plasma
membrane would require the viral RNA and Gag to move
separately to this location. Recent live-cell imaging studies indicate
that viral genomes that are otherwise highly dynamic in the
cytoplasm become anchored at the plasma membrane in the
presence of Gag, before particle assembly is detectable [43].
Therefore, it is possible that a small number of Gag molecules bind
to the viral RNA in the cytoplasm and bring it to the plasma
membrane, or that RNA binds to a small number of Gag
molecules that are already situated at the plasma membrane.
Currently, there is no available data that would support or
distinguish between either hypothesis.
The second key question about the initiating steps in particle
assembly is whether Gag forms oligomers in the cytoplasm prior to
membrane binding. Techniques that rely on epitope masking of
Gag upon multimerization [36], as well as biochemical analyses
[44,45,46,47], have shown that efficient localization to plasma
membrane correlates with the ability of Gag to undergo the
multimerization that accompanies assembly. Additionally, a
number of studies using fluorescence resonance energy transfer
(FRET) assays have also indicated that Gag multimers form
primarily at the plasma membrane [48,49,50,51,52]. Detection of
Gag multimers in the cytoplasm has been more controversial,
perhaps due to a modest degree of multimerization and exper-
imental limitations (e.g. background fluorescence in FRET assays).
Still, a number of FRET [49,51,52] and bimolecular fluorescence
complementation (BiFC) assays have suggested that some level of
Gag multimerization occurs in the cytoplasm [53,54]. However,
none of these assays can address precisely the extent and
stoichiometry of Gag multimerization in the cytoplasm of cells.
Interestingly, in vitro biochemical assays have shown that
recombinant Gag exists in monomer-dimer or monomer-trimer
equilibrium depending on buffer conditions, particularly the
presence of inositol phosphates that might mimic the presence of
membrane [55]. Whether Gag exists in a similar type of
equilibrium in the cytoplasm and whether it binds RNA as
monomers or multimers in cells is still largely unknown, although
there is some in vitro evidence obtained using truncated Gag
proteins suggests that it might bind RNA as a dimer [56].
In this study, we aimed to elucidate the initial site of Gag-RNA
interaction and whether Gag forms multimers, perhaps on viral
RNA, before recruitment to the plasma membrane. To accom-
plish this, we developed assays in which we combined subcellular
fractionation with RNA-immunoprecipitation (RNA-IP) and/or
covalent protein crosslinking. Our results indicate that Gag-RNA
interaction takes place in the cytoplasm both in transiently
transfected and in infected cells. This interaction was not affected
by the ability of Gag to localize to the plasma membrane, strongly
suggesting that the initial site of Gag-RNA interaction is the
cytoplasm. However, absence of CA-CTD led to a decrease in
immunoprecipitable Gag-RNA complexes in the cytoplasm and,
particularly, at the plasma membrane, suggesting that proper
multimerization of Gag might be important for stabilizing Gag-
RNA interactions. Crosslinking/subcellular fractionation analyses
of Gag molecules in cells showed that Gag forms high-order
multimers exclusively at the plasma membrane. In contrast, Gag
appeared predominantly as monomers, but did form low-order
multimers, in the cytoplasm. We tested whether these low-order
multimers form on viral RNA using a sequential RNA-IP assay,
which suggested that at least a fraction of Gag molecules
multimerize on a given viral genome. Taken together, our results
suggest that Gag-RNA interaction initially takes place in the
cytoplasm and involves Gag monomers or low-order multimers.
Moreover, Gag-RNA interaction per se does not induce or require
higher order Gag multimerization in the cytoplasm. Instead,
membrane interactions appear to be required to induce higher
order Gag multimerization in cells.
Results
Immunoprecipitation assay to assess HIV-1 Gag:RNA
interaction
The development of live-cell imaging techniques has allowed
the visualization of individual virion assembly events that take
place at the plasma membrane [43,57]. These studies have shown
that viral RNA, that is otherwise highly mobile, can become
anchored at the plasma membrane in the presence of Gag.
Nonetheless, Gag only becomes visible at the site of the
membrane-anchored RNA at later times, suggesting that a small
number of Gag molecules are initially responsible for retaining
viral RNA at the plasma membrane [43]. Because the initial
interaction between Gag and RNA apparently involves an
invisible number of Gag molecules, visual techniques are limited
in their ability to analyze earlier assembly events, i.e. whether the
initial Gag-RNA interaction occurs in the cytoplasm, or at the
plasma membrane.
To address this issue, we developed a quantitative RNA-IP
assay where protein-RNA complexes are immunoprecipitated and
the amount of RNA that is bound to the protein of interest is
analyzed by qRT-PCR. Since coexpression of a packageable HIV-
1 genomic RNA carrying binding sites for the bacteriophage MS2
coat protein (V1B-MS2) and the MS2-GFP fusion protein allowed
the successful visualization of viral RNA:protein complexes [43],
we first tested whether a complex of V1B-MS2 RNA and MS2-
Author Summary
Human immunodeficiency virus (HIV) assembles at the
plasma membrane of the infected host cell, resulting in the
release of infectious virus particles. HIV assembly is
directed by the viral structural protein, Gag that performs
a number of functions including specific recruitment of
viral genomic RNA and multimerization around this RNA to
form a virus particle. However, it is currently not clear
where in the cell these two key events, Gag-RNA
interaction and Gag multimerization, are initiated and
whether they are coordinated. In this study we provide
strong evidence that recruitment of viral genomic RNA by
Gag is initiated in the cytoplasm of the host cell. However,
this interaction per se does not require or induce a high
degree of Gag multimerization, as Gag is present as
monomers or dimers in the cytoplasm. In contrast, plasma
membrane seems to be the only site at which higher order
Gag multimerization occurs. Notably, at least a fraction of
the Gag dimers in the cytoplasm are bound to the viral
RNA. These results provide deeper insights to our
understanding of the molecular details of the initiating
events in HIV-1 assembly, which are potential targets for
development of new antiviral drugs.
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siently transfected with V1B-MS2 RNA and MS2-GFP expression
plasmids were processed for RNA-IP assay at 24 hours post-
transfection. As shown in Figure 1A, about 8% of the total viral
RNA in the cell lysate was immunoprecipitated by anti-GFP
antibodies. We then tested whether HIV-1 Gag-GFP could
similarly be used to immunoprecipitate a complex containing
the V1B-MS2 RNA. Indeed, V1B-MS2 RNA could also be
efficiently immunoprecipitated in a complex with Gag-GFP
(Figure 1B). The lower efficiency of RNA-IP with Gag-GFP (1
to 2% of the total RNA in the cell lysate) as compared to with
MS2-GFP may be due to the presence of multiple copies of high
affinity binding sites on viral RNA for the latter protein.
Additionally, it is important to note that the fraction of the input
viral RNA that is immunoprecipitated is determined by the
fraction of the viral RNA that is actually associated with Gag, not
simply the efficiency with which these complexes are immuno-
precipitated. One would expect that, in cells, not all genomic RNA
molecules will be associated with Gag and that not all Gag
molecules will be associated with genomic RNA. This, combined
with the fact that immunoprecipitation of a given protein is rarely
100% efficient, explains why only a proportion of the viral RNA
that is present in cells is recovered by immunoprecipitation of the
Gag protein.
Next, we analyzed the specificity of the RNA-IP assay. First,
Gag-GFP was coexpressed with either the V1B-MS2 viral RNA or
a mutant derivative, V1B-Dy -MS2, in which stem loops 3 and 4
of the packaging signal were deleted. Association of V1B-Dy -MS2
RNA with Gag was reduced by about 3 to 4-fold as compared to
V1B-MS2 RNA (Figure 1C). This data correlates with the
previously observed reduction in virion infectivity and RNA
packaging associated with the V1B-Dy -MS2 viral RNA [43]. To
test the specificity of anti-GFP immunoprecipitation, we per-
formed parallel immunoprecipitations using untagged Gag
(Figure 1D) or an irrelevant antibody, anti-FLAG (Figure 1E).
As expected, viral RNA was not immunoprecipitated using the
untagged Gag or by anti-FLAG antibodies (Figure 1D, E).
We then tested whether the immunoprecipitated Gag-RNA
complexes form in the living cell prior to lysis, or whether they
form as an artifact of cell lysis and subsequent experimental steps.
Thus, 293T cells separately expressing V1B-MS2 RNA and Gag-
GFP were mixed before cell lysis and processed for RNA-IP in
Figure 1. Efficient immunoprecipitation of HIV-1 genomes by MS2-GFP or Gag-GFP. (A and B) Lysates of 293T cells coexpressing V1B-
MS2 RNA and either MS2-GFP (A) or Gag-GFP (B) were prepared at 24-h post-transfection. RNA-protein complexes were immunoprecipitated using
anti-GFP antibodies. Immunoprecipitations without antibodies (noab) were carried in parallel. Immunoprecipitated V1B-MS2 RNA was quantitated by
qRT-PCR and is represented as fraction of input RNA prior to immunoprecipitation (% input). (C) RNA-IP assay was performed as in (B) where the viral
genome was either V1B or V1BDY.( D) RNA-IP assay in 293T cells coexpressing V1B-MS2 viral RNA and Gag-GFP or untagged Gag. (E) RNA-IP assay
was performed as in (B) but an immunoprecipitation using anti-FLAG antibodies was included as negative control. (F) 293T cells separately expressing
Gag-GFP or V1B-MS2 viral RNA were mixed before cell lysis followed by immunoprecipitation (gray bars). RNA-IP assay was then performed as in (B).
Immunoprecipitations from 293T cells that were cotransfected with Gag-GFP and V1B-MS2 plasmids were carried in parallel (black bars). Data in (A-F)
represents the average of two independent experiments, where error bars indicate the range between the averages of two experiments. RNA
extracted from 10% of the cell lysate that was used in immunoprecipitation was subjected to qRT-PCR without reverse transcription (noRT) to control
for the presence of contaminating viral DNA.
doi:10.1371/journal.ppat.1001200.g001
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indicated in Figure 1F, Gag-GFP was unable to immunoprecip-
itate the V1B-MS2 when the RNA and protein were expressed in
separate cells that were mixed before cell lysis. These results
indicate that the immunoprecipitated Gag-RNA complexes form
in the cell and that there is little, if any, association of Gag with
viral RNA after cell lysis. Taken together these results strongly
suggest that our RNA-IP assay is specific and represents
biologically relevant RNA:protein interaction events that occur
in living cells.
Interaction of HIV-1 Gag with the viral genome is
increased by CA but does not require Gag localization to
membranes
Because HIV-1 assembly requires an intact CA-CTD, and
given the possibility that proper Gag multimerization might affect
RNA binding, we performed RNA-IP assays using lysates of 293T
cells coexpressing V1B-MS2 RNA and a mutated version of Gag-
GFP that lacks the CTD of CA (Gag-delCTD-GFP). Notably,
about 5-fold less V1B-MS2 was immunoprecipitated by Gag-
delCTD, as compared to WT Gag, in terms of the fraction of the
input RNA (Figure 2A) or the absolute numbers of copies of RNA
(Figure 2B). In contrast, immunoprecipitation of cellular GAPDH
RNA by Gag-GFP was not affected by the presence or absence of
CA-CTD (Figure 2C). It should be noted that immunoprecipita-
tion of GAPDH RNA by Gag is expected, as HIV-1 particles can
package cellular mRNAs, usually in proportion to their cellular
abundance [38,58]. Interaction of Gag with GAPDH RNA,
however, was less efficient than with viral RNA (compare the
percentage of the input RNA that was immunoprecipitated in
Figure 2A and 2C).
Next, we determined whether an HIV-1 Gag mutant that
should not localize to the plasma membrane could still interact
with viral RNA. Mutation of the N-terminal glycine residue of MA
to alanine (G2A) blocks the attachment of a myristoyl group to
Gag and hence prevents its recruitment to the plasma membrane
[8,9]. Notably, G2A-Gag, unlike WT Gag, did not affect the
behavior of GFP-labeled viral RNA in cells [43], suggesting the
possibility that Gag membrane localization might be important for
RNA-Gag interactions. Interestingly, G2A-Gag-GFP immunopre-
cipitated the V1B-MS2 RNA with an efficiency that was equal to
or higher than that of WT Gag (Figure 2D, E). This result
indicates that membrane binding is not required for the
association of Gag with the viral genome and suggests that the
Figure 2. Interaction of Gag with HIV-1 genome is enhanced by an intact CA domain but not by Gag myristoylation. (A-C) V1B-MS2
viral RNA bound to either Gag-GFP (black bars) or Gag-delCTD-GFP (gray bars) was immunoprecipitated by anti-GFP antibodies from lysates of 293T
cells. Immunoprecipitations without antibodies (noab) were included in parallel as controls. (D-F) V1B-MS2 viral RNA bound to either Gag-GFP (black
bars) or Gag-G2A-GFP (gray bars) was immunoprecipitated by anti-GFP antibodies as in (A-C). Immunoprecipitated RNA was quantitated by qRT-PCR
to detect viral RNA (A, B, D, E) or cellular GAPDH RNA (C, F) as described in Materials & Methods and is represented either as fraction of input material
prior to immunoprecipitation (% input) or copies of DNA per ml of reverse transcribed template (copy no/ml). Data represents the average of two
independent experiments, where error bars indicate the range between the averages of two experiments. noRT= as explained in legend to Figure 1.
doi:10.1371/journal.ppat.1001200.g002
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delCTD, G2A-Gag also immunoprecipitated GAPDH RNA at a
similar efficiency to that of WT Gag (Figure 2F). Taken together,
these results suggest that viral genome packaging is initiated by
Gag:RNA interactions in the cytoplasm and that Gag:RNA
interactions are, in part, dependent on the presence of an intact
CA-CTD.
Analysis of HIV-1 Gag interactions with viral genomes in
subcellular fractions
To analyze more directly whether Gag interacts with viral RNA
in the cytoplasm, we coupled the RNA-IP assay to membrane
flotation analyses. Lysates of 293T cells transiently expressing
Gag-GFP, G2A-Gag-GFP or Gag-delCTD-GFP together with
V1B-MS2 were separated using membrane flotation gradients and
ten 1 ml fractions of the gradient were collected. In this assay,
membranes and associated proteins concentrated mainly in
fraction 3, whereas the cytoplasmic content remained in fractions
9 and 10. We isolated total RNA and proteins from each fraction
and analyzed each for the presence of the viral and cellular RNA
as well as Gag proteins. Additionally, RNA-IP assays were
performed on fractions 3 (membranes) and 10 (cytoplasm).
In the presence of WT Gag-GFP, viral RNA and Gag-GFP
localized to two peaks in the gradient corresponding to the
membrane and cytoplasmic fractions (Figure 3A, 3B). Surprisingly,
even though Gag-delCTD-GFP was less efficient than WT Gag-
GFP in immunoprecipitating viral RNA from total cell lysates
(Figure 2A, B), it was fully capable of recruiting viral RNA to the
membrane fraction (Figure 3A). As expected, there was signifi-
cantly less viral RNA in the membrane fraction in the presence of
G2A-Gag-GFP (Figure 3A), which did not itself appear in the
membrane fractions (Figure 3B). These results suggest that
recruitment of viral RNA to the plasma membrane is independent
of CA-mediated Gag multimerization but is simply a function of
Gag membrane localization. In contrast to viral RNA, the
presence of a relatively low level of GAPDH RNA in the
membrane fraction was unaffected by Gag or mutant versions
thereof (Figure 3C). The presence of GAPDH RNA in the plasma
membrane fraction likely represents nonspecific association of
RNA and membranes, perhaps as a result of resealing of
membranous vesicles following dounce homogenization. This idea
is supported by the finding that a similarly low level of V1B-MS2
RNA in the membrane fraction was observed even in the absence
of Gag (data not shown). It should be emphasized that there were
approximately 300–400 fold lower concentrations of GAPDH
RNA in the membrane fraction as compared to the cytoplasmic
fraction (Figure 3C). In contrast, in the presence of WT Gag-GFP,
viral RNA was present in the membrane fraction at about 10% of
the concentration in the cytoplasm fraction (Figure 3A).
The presence of Gag-RNA complexes at the plasma membrane
and in the cytoplasm were examined by performing RNA-IP
assays using fractions 3 and 10 of the membrane flotation
gradients, respectively. As expected, WT Gag was able to
efficiently coprecipitate viral RNA from the membrane fraction
(Figure 3D). Surprisingly, even though Gag-delCTD-GFP could
localize to the membrane fraction (Figure 3B) and recruit viral
RNA to this fraction as efficiently as WT Gag (Figure 3A), it was
not able to efficiently coprecipitate viral RNA from this fraction
(Figure 3D). It is likely that Gag-delCTD forms a complex with
RNA that is insufficiently stable to effectively survive the
immunoprecipitation procedure. This idea is consistent with
previous imaging studies in which Gag-delCTD was observed to
be diffusely distributed at the plasma membrane and that some
RNA molecules anchored at the plasma membrane by Gag-
delCTD were found to dissociate after a few minutes [43]. As
expected, RNA-IP from the membrane fraction of cells expressing
G2A-Gag did not yield detectable viral RNA as this protein does
not localize and recruit viral RNA to the plasma membrane (data
not shown).
In parallel with our findings using total cell lysates (Figure 2),
Gag-GFP and G2A-Gag-GFP coprecipitated viral RNA with
almost equal efficiencies from the cytoplasmic fraction, but the
ability of Gag-delCTD to immunoprecipitate viral RNA appeared
comparatively diminished (Figure 3E). Thus, these results indicate
that Gag-viral RNA complexes can form in the cytoplasm and that
their stability is, in part, dependent on the presence of intact CA.
We emphasize that the Gag-RNA complexes analyzed in this
assay do not form as a consequence of cell lysis and further
manipulations but represent events that take place in the cell.
Evidence for this is provided by mixing experiments where cells
separately expressing Gag-GFP and V1B-MS2 RNA were mixed
before cell lysis and processed for membrane flotation and RNA-
IP from cytoplasmic fractions in parallel with cells coexpressing
Gag-GFP and viral RNA. Similar to our observations using total
cell lysates (Figure 1F), mixing cells that separately express Gag-
GFP and viral RNA before cell lysis did not yield detectable Gag-
RNA complexes in the membrane and cytoplasmic fractions (data
not shown).
Gag interacts with viral RNA in the cytoplasm of HIV-1
infected cells
In order to examine the interaction of Gag with viral RNA in a
more physiologically relevant context, we repeated the membrane
flotation/RNA-IP experiments in infected cells. Specifically, MT2
cells were infected with an HIV-1 derivative carrying the
immunoprecipitation tag (YFP) in the stalk region of MA and an
inactive protease (NL4-3 MA-YFP/PR-). This defective genome
was introduced into MT2 cells using VSV-G pseudotyped virions
that were generated with an excess of complementing WT HIV-1
GagPol proteins. Thus, the virions were infectious for only a single
cycle and the infected MT2 cells expressed, de novo, the YFP-
tagged, PR-defective Gag and GagPol proteins. At 48 h after
infection, these infected cells were fractionated by membrane
flotation and processed as above. As expected, the Gag-MA-YFP
protein was present in both the membrane and the cytoplasmic
fractions (Figure 4A). Similarly the viral RNA was present in two
peaks in the gradient corresponding to the membrane and
cytoplasmic fractions (Figure 4B). Compared with transfected
293T cells (Figure 3A), recruitment of viral RNA to the plasma
membrane appeared more efficient in infected cells, as indicated
by the similar concentrations viral RNA in membrane and
cytoplasmic fractions (Figure 4B). This may be due to a more
optimal balance of virion RNA and Gag protein levels in infected
as opposed to transfected cells. As expected, GAPDH RNA was
present at much lower levels in the plasma membrane fraction
compared with the cytoplasmic fraction of infected MT2 cells
(Figure 4C), suggesting that the membrane-associated viral RNA
represents specific recruitment by Gag.
Next, viral RNA-Gag complexes were immunoprecipitated
from the membrane and cytoplasmic fractions of infected MT2
cells. In agreement with transient transfection based assays, Gag-
RNA complexes were successfully isolated from both the
cytoplasmic and membrane fractions (Figure 4D, E). The
efficiency of immunoprecipitation for viral RNA in the membrane
fraction was lower than the cytoplasmic fraction (Figure 4D, E),
even though these fractions contained almost equal amounts of
viral RNA prior to immunoprecipitation (Figure 4B). This may be
due to inaccessibility of the YFP immunoprecipitation tag at the
Initiating Events in HIV-1 Assembly
PLoS Pathogens | www.plospathogens.org 5 November 2010 | Volume 6 | Issue 11 | e1001200Figure 3. Immunoprecipitation of HIV genomic RNA from membrane and cytoplasmic fractions by Gag, G2A-Gag and Gag-delCTD.
(A-E) 293T cells coexpressing V1B-MS2 and either Gag-GFP, G2A-Gag-GFP or Gag-DCTD-GFP were processed for subcellular fractionation at 24-h
post-transfection. Ten fractions from the top of the membrane flotation gradient were collected. Total RNA and proteins from these fractions were
isolated as explained in Materials & Methods. (A and C) V1B-MS2 (A) and GAPDH (C) RNA in fractions were quantitated by qRT-PCR. Data is
represented as the relative number of copies of cDNA with as compared to the tenth, cytoplasmic fraction of Gag-GFP sample that was arbitrarily set
to a value of 100%. (B) Western blot analysis of Gag-GFP, G2A-Gag-GFP and Gag-DCTD-GFP in sucrose fractions and in post-nuclear supernatant (PNS)
using anti-HIV-1 MA antibodies. (D and E) After subcellular fractionation, immunoprecipitations from the membrane (D) and cytoplasmic (E) fractions
were performed using anti-GFP antibodies as explained in Materials & Methods. Parallel immunoprecipitations were carried in the absence of
antibodies (noab). Immunoprecipitated V1B-MS2 RNA is quantitated by qRT-PCR and is represented as a fraction of input material prior to
immunoprecipitation (% input, [D, E]). Data in (A, C, D, E) represents the average of two independent experiments where error bars indicate the
range. noRT= as explained in legend to Figure 1.
doi:10.1371/journal.ppat.1001200.g003
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PLoS Pathogens | www.plospathogens.org 6 November 2010 | Volume 6 | Issue 11 | e1001200Figure 4. Immunoprecipitation of genomic viral RNA from membrane and cytoplasmic fractions of HIV-1 infected MT2 cells. (A-F)
MT2 cells were infected with VSV-G pseudotyped NL4-3 MA-YFP/PR- at MOI=1 and processed for subcellular fractionation at 48-h post-infection. Ten
fractions from the top of the membrane flotation gradient were collected. Total RNA and proteins from these fractions were isolated as explained in
Materials & Methods. (A) Western blot analysis of MA-YFP Gag in sucrose fractions and in post-nuclear supernatant (PNS) using anti-HIV-1 CA
antibodies. (B and C) Viral (B) and GAPDH (C) RNA in fractions was quantitated by qRT-PCR. Data is represented as the relative number of copies of
cDNA as compared to the tenth, cytoplasmic fraction sample that was arbitrarily set to a value of 100%. (D-F) Immunoprecipitations from the
membrane (black bars) and cytoplasmic (gray bars) fractions were performed using anti-GFP antibodies. Parallel immunoprecipitations without
antibodies (noab) were included as controls. Immunoprecipitated viral RNA (D and E) or GAPDH RNA (F) was quantitated by qRT-PCR and is
represented as either fraction of input material prior to immunoprecipitation (% input) or number of copies of cDNA per ml of PCR template. Data in
(B-F) represents the average of two independent experiments where error bars indicate the range. noRT= as explained in legend to Figure 1.
doi:10.1371/journal.ppat.1001200.g004
Initiating Events in HIV-1 Assembly
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extensive. Indeed, Gag epitope occlusion during particle assembly
has been observed before by others [36]. Immunoprecipitation of
GAPDH mRNA was much less efficient than viral RNA in both
the membrane and cytoplasmic fractions (Figure 4F) in parallel
with experiments using transfected cell lysates (Figure 2C, F).
Nevertheless, in support of our findings using transfection-based
assays, these results clearly show that immunoprecipitable Gag-
RNA complexes form in the cytoplasm of HIV-1 infected cells.
HIV-1 Gag can from low order multimers in the
cytoplasm but requires membrane binding for high
order multimerization in cells
The above results strongly suggest that Gag can bind to viral
RNA while in the cytoplasm. A number of in vitro [55,56] and in
vivo [49,51,52,53,54] findings have suggested that Gag multi-
merization might be initiated in the cytoplasm of cells, perhaps
triggered by RNA binding. However, none of these assays could
address the extent or stoichiometry of Gag multimerization in
cells. The fact that Gag, G2A-Gag and Gag-delCTD immuno-
precipitate viral RNA at different efficiencies prompted us to
analyze whether these proteins could form multimers in the
cytoplasm of cells, and how the extent of multimerization in the
cytoplasm compared with that at the plasma membrane. We used
a chemical crosslinking approach in which 293T cells coexpressing
Gag, G2A-Gag or Gag-delCTD and viral RNA were crosslinked
by EGS, a membrane permeable crosslinker, and then analyzed
using membrane flotation assays. Proteins from membrane and
cytoplasmic fractions were precipitated, delipidated and analyzed
in parallel with post-nuclear supernatants and mock-crosslinked
samples by western blotting.
The majority of the WT Gag protein was crosslinked and
clearly formed high-order multimers at the plasma membrane
(Figure 5A, B). A fraction of Gag was present as monomers
(Figure 5A, B), perhaps due either to incomplete crosslinking by
EGS or incomplete assembly. Notably, Gag-delCTD, which does
not assemble into particles, also formed high-order multimers at
the plasma membrane (Figure 5A, lane 3), however the extent of
this multimerization was significantly reduced as compared to WT
Gag (Figure 5A, B). Higher order multimerization of Gag-delCTD
was somewhat unexpected given that CA-CTD participates in
Gag-Gag interactions and is essential for particle assembly.
Presumably other domains of Gag, such as MA, the CA-NTD
and/or NC, are in contact with each other and can be crosslinked
by EGS leading to the observed pattern of Gag-delCTD
multimers.
Notably, none of the Gag proteins formed high-order multimers
in the cytoplasm, although cytoplasmic low-order Gag multimers
(i.e. dimers) were apparent in each case (Figure 5A, lanes 4, 5, 6).
A minor caveat is that the G2A Gag protein appeared to be
somewhat prone to breakdown; thus the smeared appearance of
G2A-Gag dimers in the cytoplasm is likely due to multimerization
between intact Gag-G2A and its degradation products (Figure 5A,
lane 5). Nonetheless, G2A-Gag and Gag-delCTD dimers were as
or more abundant than were WT Gag dimers in the cytoplasm
(Figure 5B). Taken together, these results indicate that Gag forms
only low order multimers in the cytoplasm and that the different
Figure 5. Multimerization of Gag, G2A-Gag, Gag-delCTD in plasma membrane and cytoplasm. 293T cells coexpressing FLAG and HA-
tagged Gag or its derivatives (G2A-Gag or Gag-delCTD) together with V1B-MS2 viral RNA were cross-linked by treatment with 1mM EGS and used in
membrane flotation assay. (A) Western blot analysis of Gag, G2A-Gag and Gag-delCTD in membrane fractions (lanes 1–3), cytoplasmic fractions (lanes
4–6), post-nuclear supernatants (PNS, lanes 7–9) and in mock crosslinked post-nuclear supernatants (lanes 10–12) using mouse anti-FLAG antibodies.
(B) Quantitative analysis of membrane (lanes 1–3) and cytoplasmic (lanes 4–6) fractions of the western blot in (A). x-axis shows the pixel location and
y-axis indicates the average pixel intensity in the lane that is analyzed. Degree of Gag multimerization is marked by subscripts (i.e. Gag3 corresponds
to Gag trimers).
doi:10.1371/journal.ppat.1001200.g005
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by the extent to which they multimerize in the cytoplasm. These
results also suggest that high-order Gag multimers are neither
required for, nor induced upon, binding of Gag to viral RNA in
the cytoplasm. Rather, high order Gag multimerization requires
Gag to bind to membrane.
Gag can form multimers on viral RNA in the cytoplasm
Since we observed that a fraction of Gag forms low-order
multimers in the cytoplasm, we directly tested whether viral RNA
was associated with multimeric, cytoplasmic Gag. Specifically, we
performed a sequential RNA-IP (seq-RNA-IP) assay in 293T cells
co-expressing FLAG- and HA-tagged Gag proteins together with
viral RNA. After dual crosslinking by EGS and formaldehyde,
total cell lysates were used in immunoprecipitation assays using
anti-HA or anti-FLAG antibodies. The eluates from these first
immunoprecipitations were then used in a second round of
immunoprecipitation using anti-FLAG or anti-HA antibodies,
respectively, and the viral RNA content of first and second round
immunoprecipitations was evaluated by qRT-PCR.
Analyses of the first immunoprecipitations indicated that WT
Gag and G2A-Gag immunoprecipitated viral RNA at similar
levels, whereas Gag-delCTD exhibited a decreased level of viral
RNA coprecipitation (Figure 6A, B). This result is in general
agreement with RNA-IP results from cell lysates in the absence of
crosslinking (Figure 2), but it should be noted that these
immunoprecipitations yielded a smaller fraction of the input
RNA (,0.1–0.2% of the input RNA was detected in a single
round of immunoprecipitation) likely due to the fact that RNA
chemical crosslinking and milder elution conditions were
employed.
When the initial immunoprecipitation with anti-HA antibody
was followed by a second immunoprecipitation with an anti-FLAG
antibody, viral RNA was easily detected after a second round of
Figure 6. Gag molecules form multimers on viral RNA. 293T cells coexpressing FLAG and HA-tagged Gag or its derivatives (G2A-Gag or Gag-
delCTD) together with V1B-MS2 viral RNA were used in seq-RNA-IP analysis after crosslinking with EGS and formaldehyde. (A, B) Viral RNA that was
eluted after the first immunoprecipitation with anti-HA or anti-FLAG antibodies, or in the absence of antibodies (noab) is quantitated by qRT-PCR as
in previous figures. (C, D) RNA-protein complexes obtained from the first immunoprecipitation (A, B) were used in a subsequent
immunoprecipitation. Order of immunoprecipitations is indicated on the x-axis. Data is represented as either number of copies of cDNA per mlo f
PCR template (A, C) or fraction of input material (% input, B, D). Data in (A-D) shows the average of two independent experiments where error bars
indicate the range.
doi:10.1371/journal.ppat.1001200.g006
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(Figure 6C). Similar results were obtained when the order of
immunoprecipitation was reversed (HA followed by FLAG or
FLAG followed by HA, Figure 6C). Interestingly, when the second
round seq-RNA-IP efficiencies were compared, Gag, G2A-Gag
and Gag-delCTD all appeared a to be present as multimers on the
viral RNA at similar levels (Figure 6D). Specifically. if two different
proteins simultaneously associate with a given RNA, then the
expected outcome in a seq-RNA-IP assay is to observe a
significantly higher enrichment of RNA during the second
immunoprecipitation, as opposed to the first [59]. Note, however,
that even if all viral RNA molecules are bound by Gag dimers, not
all Gag-HA molecules will multimerize with Gag-FLAG molecules
on the viral RNA. Rather, there will be a distribution of
homodimeric (HA-HA or FLAG-FLAG) and heterodimeric
(HA-FLAG) Gag molecules on the viral RNA. Importantly, the
fraction of RNA that was immunoprecipitated during the second
round of immunoprecipitation was significantly enhanced (,20-
fold) in both HA-FLAG and FLAG-HA seq-RNA-IPs (compare
values in Figure 6B and 6D). This result strongly suggests that Gag
forms multimers in association with at least a fraction of viral
RNA.
Notably, even though seq-RNA-IP assays were done on total
cell lysates, the G2A-Gag mutant that cannot localize to the
plasma membrane (Figure 3, 5) exhibited a similar degree of
multimerization on viral RNA in the seq-RNA-IP assay as did the
WT Gag protein. This finding suggests that the detection of viral
RNA in the sequential immunoprecipitation was primarily a result
of Gag-RNA binding events that occurred in the cytoplasm. We
therefore suggest that at least a fraction of the low-order Gag
multimers detected in the cytoplasm (Figure 5) were bound to viral
RNA.
Discussion
Given the comparative absence of information about the events
that initiate HIV-1 assembly in living cells, we adopted a variety of
strategies to analyze this process in cells. First, we developed a
quantitative RNA-IP assay that was sensitive, specific and
represented Gag-RNA interactions that take place in cells. By
coupling this assay to membrane flotation analyses, we were able
to show that HIV-1 Gag-RNA complexes form in the cytoplasm of
both transiently transfected and infected cells. The fact that
formation of these complexes was independent of the ability of
Gag to localize to membranes suggests that the cytoplasm is the
site where HIV-1 RNA packaging is initiated. Interestingly, the
Gag protein of Rous sarcoma virus (RSV) was shown to require
nuclear localization for efficient genome packaging [60,61],
whereas the Gag protein of feline immunodeficiency virus was
shown to colocalize with viral RNA at the nuclear envelope [62].
Although our results do not exclude the possibility that Gag-RNA
interactions are initiated in the nucleus, the presence of little, if
any, Gag in the nucleus at steady-state [6,57,62] makes it difficult
to perform biochemical analyses that could reveal such events, if
they were to occur. Nonetheless, the ability of HIV-1 RNA to be
packaged requires it to be exported from the nucleus, but the
precise export pathway taken by the RNA does not appear to be
critical [63]. This suggests that RNA packaging by Gag is initiated
in the cytoplasm. A remaining question is whether there are
distinct locations in the cytoplasm where HIV-1 Gag interacts with
viral RNA or whether Gag-RNA interaction is a stochastic
process, where diffusing Gag and RNA molecules form stable
complexes randomly as they encounter each other. The mobility
of both Gag and viral RNA in the cytoplasm [43,64] and the
apparently rather non-selective interaction of Gag with cellular
RNAs [58] is more consistent with the latter hypothesis.
The stability of Gag-RNA complexes both in the cytoplasm and
plasma membrane seemed to depend on the CTD of CA, as
evidenced by the reduced ability of Gag-delCTD to immunopre-
cipitate viral RNA. It is likely that the Gag-delCTD/RNA
complexes disintegrate during immunoprecipitation, rather than
fail to form efficiently in the cell, as Gag-delCTD was fully capable
of recruiting viral RNA to the plasma membrane. This finding is
in agreement with previous imaging experiments, which revealed
that some viral RNA molecules recruited by Gag-delCTD
dissociate from the plasma membrane [43]. Given that Gag-
delCTD formed multimers at the plasma membrane less
extensively than WT Gag, these results might also suggest a role
for higher-order Gag multimerization in stabilizing Gag-RNA
interactions at the plasma membrane. Alternatively, it is possible
that the conformation of Gag in the context of a multimer is
influenced by the CA-CTD so as to increase its intrinsic RNA
binding affinity – perhaps CA-CTD:CA-CTD contacts optimally
position the linked NC domains to better recognize the viral RNA
psi sequence.
Even though a number of FRET and BiFC studies indicated
that plasma membrane is the major site of Gag multimerization,
there has been inconsistency in the published conclusions about
whether and to what extent HIV-1 Gag forms multimers in the
cytoplasm [48,49,50,51,52,53,54]. Our results are the first to show
that a fraction of Gag in the cytoplasm appeared as dimers, but we
were not able to detect higher-order Gag multimers in the
cytoplasm. Of note, higher levels of G2A-Gag and Gag-delCTD
dimers were detected in the cytoplasm as compared to WT Gag. A
possible explanation for this observation could be that soon after
binding to the viral RNA as low-order multimers, the WT Gag-
RNA complexes acquire higher affinity for, or move to, the plasma
membrane, where further oligomerization takes place. Thus, a
block in membrane binding (in G2A-Gag) or a decrease in the
stability of Gag-RNA interactions (in Gag-delCTD) might lead to
the accumulation of dimers in the cytoplasm. In contrast to
cytoplasmic Gag, plasma membrane-associated Gag molecules
formed high order multimers. It was noticeable that Gag-delCTD
also formed multimers with apparently similar stoichiometry to
WT Gag at the plasma membrane (albeit to lesser extent), even
though it is completely incapable of assembling into particles.
These multimers are presumably formed by Gag:Gag contacts in
MA, CA-NTD or NC domains of Gag. This finding, however,
reinforces the finding that localization to the plasma membrane
seems to be required for high order Gag multimerization in cells.
Although we cannot exclude the possibility that only a fraction
of the Gag dimers detected in the cytoplasm are bound to viral
RNA, sequential RNA-IP assays suggest that at least a fraction of
Gag molecules form multimers on viral RNA in the cytoplasm.
Gag dimerization on viral RNA is likely mediated by RNA
sequences around the packaging signal. However, these results do
not distinguish between the possibilities that Gag dimers in the
cytoplasm form on a single viral RNA molecule or are present on
RNA dimers [65]. The latter possibility would require the
presence of Gag molecules at a distance of, at the most, 16.1 A ˚
from each other, the spacer arm length of EGS that was used for
crosslinking. Currently there is no structural evidence that would
favor either of these possibilities over the other.
Overall, our findings suggest that HIV-1 genome packaging is
initiated in the cytoplasm. This Gag:RNA interaction does not
require or induce high-order Gag multimerization in the
cytoplasm, but may involve Gag dimers or low-order multimers,
that also form in the cytoplasm. This initial Gag:RNA complex is
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Gag-viral RNA complex is recruited to the plasma membrane
where high-order Gag multimerization occurs and virion assembly
is completed.
Materials and Methods
Cell lines, viruses and infections
293T (ATCC #: CRL-11268) cells were obtained from ATCC
and grown in DMEM supplemented with 10% fetal bovine serum.
MT-2 cells, obtained from the NIH AIDS Research and
Reference Reagent Program, were cultured in RPMI supplement-
ed with 10% fetal bovine serum.
VSV-G pseudotyped NL4-3 (MA-YFP/PR-) viruses were
produced by transfection of 293T cells with the proviral plasmid,
a complementing codon-optimized Gag-Pol expression plasmid
and VSV-G expression vector using polyethyleneimine (Poly-
Sciences, Warrington, Pennsylvania, United States) as described
previously [66]. Virus titers were determined by FACS analysis of
target MT-2 cells. Infections were initiated in media containing
5 mg/ml polybrene and input viruses were removed at 6–8 hours
post-infection by washing cells several times in complete medium.
Plasmids
Construction of plasmids expressing codon-optimized HIV-1
Gag-GFP (pCR3.1/HIV-Gag-GFP) [67] and MS2-GFP [43] was
described previously. pCR3.1/HIV-Gag-G2A, lacking the myr-
istoylation signal, and pCR3.1/HIV-Gag-dCTD, lacking the C-
terminal domain of capsid, were previously described [43,67] and
were used to generate the GFP-tagged versions. For constructing
HA- and FLAG-tagged Gag proteins, oligonucleotides coding for
three consecutive copies of HA and FLAG tags flanked by NotI
and XhoI restriction endonuclease sites were annealed in vitro and
cloned into NotI-XhoI digested pCR3.1/HIV-Gag-GFP, G2A-
GFP and dCTD-GFP plasmids.
Construction of proviral plasmids V1B, V1B-MS2 and V1B-D
y-MS2 was previously described [43,68]. NL4-3-derived MA-
YFP/PR- proviral plasmid was generated by ligating an AgeI/
SpeI fragment of NL4-3/PR- encoding an inactive protease, to
AgeI/SpeI-digested NL4-3/MA-YFP plasmid, which incorporates
YFP into the stalk region of MA [6].
Antibodies
Antibodies used in RNA-immunoprecipitation, sequential-
RNA-immunoprecipitation and western blot assays were as
follows: mouse monoclonal anti-GFP (Roche), mouse monoclonal
anti-FLAG (Sigma), mouse monoclonal anti-HA (HA.11 Cov-
ance), rabbit polyclonal anti-HIV-1 MA (NIH), mouse monoclonal
anti-HIV-1 p24CA (183-H12-5C).
RNA immunoprecipitation and data analysis
RNA immunoprecipitation (RNA-IP) assay was performed as
described previously with minor modifications [69]. Briefly, 1610
7
cells were lysed in 250 ml of polysome lysis buffer (10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.0,
0.1 M potassium chloride, 5 mM magnesium chloride, 25 mM
EDTA, and 0.5% Nonidet P-40, 2 mM DTT) supplemented with
SuperaseIN (Ambion) and protease inhibitors (Roche). After
preclearing with Protein G-sepharose beads (GE Healthcare),
lysates were diluted in immunoprecipitation buffer (50 mM Tris-
HCl pH 7.4, 150 mM sodium chloride, 1 mM magnesium
chloride, 0.05% Nonidet P-40, 1 mM DTT, 15 mM EDTA,
supplemented with RNaseOUT). Immunoprecipitations were
performed overnight at 4uC in the presence of 5-10 mg of antibody
followed by incubation with Protein G-sepharose beads for
another 4–5 hours. Parallel immunoprecipitations in the absence
of antibody were included as controls. After several washes with
NT2 buffer (50 mM Tris-HCl pH 7.4, 150 mM sodium chloride,
1 mM magnesium chloride, 0.05% Nonidet P-40), RNA was
eluted by proteinase K (Roche) treatment and purified by
phenol:chloroform extraction and ethanol precipitation. RNA
was further purified by DNase (Roche) treatment and one more
round of phenol:chloroform extraction and ethanol precipitation.
For quantitation of the RNA-IP assay, RNA samples were
reverse-transcribed using ImProm-II Reverse Transcription sys-
tem (Promega). The resulting cDNA was used as template for
quantitative real-time PCR (qRT-PCR) using ABI 7500 Fast RT-
PCR system. Viral RNA (V1B-MS2 or NL4-3 and its derivatives)
was detected by previously described primer-probe pairs [70] and
Fast Start TaqMan Probe master mix (Roche). Detection of V1B-
MS2DY and GAPDH RNA was done by a SYBR Green-based
assay with the following primer pairs:
V1B-MS2DY:F :5 9 CAAATGGTACATCAGGCCATATC-
ACCT and R: 59 TCCTTCTGATAATGCTGAAAACATGGG-
TAT;
GAPDH: F: 59 AGGTCATCCCTGAGCTGAAC and R: 59
GCAATGCCAGCCCCAGCGTC
A standard curve using serial threefold dilutions of input
samples (10% to 0.04% of the input) or known copy numbers of
NL4-3 plasmid was generated to quantitate the signals from
immunoprecipitation samples.
Sequential RNA immunoprecipitation
For sequential RNA immunoprecipitation (seq-RNA-IP) assays,
1610
7 293T cells were co-transfected with 4 mg of FLAG-tagged
Gag, G2A-Gag or Gag-delCTD, 4 mg of HA-tagged Gag, G2A-
Gag or delCTD-Gag and 2 mg V1B-MS2 expression plasmids. At
24 hours post-transfection, cells were crosslinked by 1 mM
ethylene glycol bis [succinimidylsuccinate] (EGS, Pierce) for
30 min followed by 1% formaldehyde for 10 min at room
temperature. Crosslinking was stopped by the addition of
100 mM Tris-Cl and 100 mM glycine. Cells were then washed
in 1X PBS three times, resuspended in 500 ml of radioimmuno-
precipitation assay buffer (50 mM Tris [pH 7.4], 150 mM NaCl,
1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate), supplemented with protease and RNase
inhibitors and sonicated three times for 20 seconds at power
setting 2.5 of a model 550 Sonic Dismembrator (Fisher Scientific).
Lysates were precleared by centrifugation and protein-G sephar-
ose bead incubation for 1 hour at 4uC. Immunoprecipitations
were performed as in the RNA-IP assay described above using
anti-HA and anti-FLAG antibodies. After the first immunopre-
cipitation, protein-RNA complexes were eluted by a 10-minute
incubation of Protein G beads in 150 ml elution buffer (1% SDS,
0.1M NaHCO3)a t6 5 uC. Sixty ml of the eluates were then
subjected to a second immunoprecipitation. After the second
immunoprecipitation, RNA was eluted by Proteinase K treatment.
Formaldehyde crosslinking was reversed by incubation at 65uC for
two hours and RNA was further purified as in the RNA-IP assay
described above.
Membrane flotation assay (equilibrium flotation
centrifugation)
The membrane flotation assay was based on a previously
described protocol [71]. In brief, approximately 1610
7 cells were
washed three times with NTE buffer (100 mM NaCl, 10 mM Tris
[pH 7.4], 1 mM EDTA) and resuspended in 500 ml of hypotonic
buffer (10 mM Tris [pH 7.4], 1 mM EDTA) supplemented with
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tion and adjusted to 150 mM NaCl and 1 mM MgCl2. Nuclei and
intact cells were removed by centrifugation for 10 minutes at
10006g,4 uC. Thereafter, 350 ml of supernatant was mixed with
1650 ml of 90% sucrose solution (prepared in 150 mM NaCl,
10 mM Tris [pH 7.4], 1 mM EDTA, 1 mM MgCl2) and over-
layed with 6.5 ml of 65% and 2.5 ml of 10% sucrose solutions
prepared similarly and supplemented with protease inhibitors.
When necessary, RNase inhibitors (RNaseOUT and SuperaseIN)
were added to the solutions and buffers listed above. Centrifuga-
tion was performed in a Beckman SW41 Ti rotor at 35,000 rpm
for 18 h. Ten fractions (1 ml each) were collected from the top of
the gradient and used for RNA-IP, RNA extraction or protein
analyses by western blotting.
In cases where membrane flotation assay was coupled to the
RNA-IP assay, 400 ml of the membrane (3
rd fraction) or
cytoplasmic fractions (10
th fraction) were diluted in 2X immuno-
precipitation buffer. The remainder of the immunoprecipitation
protocol was carried out as described in the above RNA-IP
protocol.
For profiling the viral and cellular RNA, 40 ml of each sucrose
fraction was resuspended in 200 ml of the RNA-IP assay elution
buffer. RNA was then purified and quantitated as indicated in the
RNA-IP protocol.
The remaining material from fractions was precipitated
overnight by trichloroacetic acid (TCA) at a final concentration
of 10%. Precipitated protein was collected by centrifugation and
washed twice with 10% TCA and once with ice-cold acetone.
Samples were air-dried briefly and resuspended in SDS-PAGE
loading buffer for analysis by western blotting.
Crosslinking-based Gag multimerization assay
Approximately 1610
7 293T cells, transiently expressing Gag
and its derivatives were collected in 1X PBS and crosslinked by
treatment with 1 mM EGS, a membrane-permeable crosslinker.
After 30-minutes of incubation at room temperature, crosslinking
was stopped by addition of Tris-Cl at a final concentration of
100 mM. Cells were then subjected to the membrane flotation
assay as indicated above. After TCA precipitation of membrane
and cytoplasmic fractions (3
rd and 10
th fractions from the top of
the gradient respectively), samples were resuspended in 9M Urea/
2% Triton X-100 and delipidated by methanol:chlorofom
extraction [72]. Proteins were separated on NuPAGE 3–8%
Tris-Acetate gels (Invitrogen) and transferred to nitrocellulose
membranes. Blots were probed with mouse anti-FLAG antibodies,
followed by goat anti-mouse antibodies conjugated to IR-
Dye800CW. Fluorescent signals were detected and quantitated
using a LICOR Odyssey scanner. ImageJ software (National
Institutes of Health, Bethesda, MD) was used for quantitative
analysis of Gag multimerization.
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